• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Haky Moon

Articles by Haky Moon

Ribo expanding RNA work in China with Ionis antisense deal

April 27, 2017
By Haky Moon
HONG KONG – A deal inked between Carlsbad, Calif.-based Ionis Pharmaceuticals Inc. and Kunshan, China-based Suzhou Ribo Life Science Co. Ltd. will ease the U.S. company's entry into the Chinese innovative drug market, while Ribo picks up a license for two antisense drugs – and an option for a third – aimed at treating metabolic diseases and cancer.
Read More

Samsung wins first U.S. biosimilar approval as FDA clears Renflexis

April 26, 2017
By Haky Moon

HONG KONG – Samsung Bioepis Co. Ltd.'s biosimilar Renflexis (infliximab-abda) will be the first product of the conglomerate's biologics arm to be marketed in the U.S. and only the second infliximab biosimilar in the market after Pfizer Inc.'s Inflectra. Samsung Bioepis gained FDA approval late Friday for its BLA for Renflexis (formerly SB2), a biosimilar candidate referencing Remicade (infliximab, Janssen Biotech Inc.).


Read More

Samsung wins first U.S. biosimilar approval as FDA clears Renflexis

April 25, 2017
By Haky Moon
HONG KONG – Samsung Bioepis Co. Ltd.'s biosimilar Renflexis (infliximab-abda) will be the first product of the conglomerate's biologics arm to be marketed in the U.S. and only the second infliximab biosimilar in the market after Pfizer Inc.'s Inflectra. Samsung Bioepis gained FDA approval late Friday for its BLA for Renflexis (formerly SB2), a biosimilar candidate referencing Remicade (infliximab, Janssen Biotech Inc.).
Read More

Canon's brand new med-tech unit needs more time according to Moody s analyst

April 24, 2017
By Haky Moon

Taiwan aims to boost med-tech sector to more than $6B valuation, challenges still lie ahead

April 17, 2017
By Haky Moon

Indian regulator clears first autologous dendritic cell-based I-O product

April 12, 2017
By Haky Moon
HONG KONG – In a country where just seven new oncology drugs were introduced in the last five years, the recent approval of Apac Biotech Pvt. Ltd.'s first-of-its-kind autoimmune therapy marked a significant step forward.
Read More

Indian regulator clears first autologous dendritic cell-based I-O product

April 12, 2017
By Haky Moon
HONG KONG – In a country where just seven new oncology drugs were introduced in the last five years, the recent approval of Apac Biotech Pvt. Ltd.'s first-of-its-kind autoimmune therapy marked a significant step forward.
Read More

Asian companies trickle into Scotland despite Brexit uncertainties

April 10, 2017
By Haky Moon

Alteogen transfers tech to China company for biosimilar development

April 5, 2017
By Haky Moon
HONG KONG – A deal between South Korean biopharmaceutical firm Alteogen Inc. and Chinese company Qilu Pharmaceutical Co. Ltd. to complete development of a biosimilar drug suggests the technology gap between the two countries is closing, and underlines the fact that recent political tensions between the two countries have had little impact on the biotech industry.
Read More

Alteogen transfers tech to China company for biosimilar development

April 3, 2017
By Haky Moon
HONG KONG – A deal between South Korean biopharmaceutical firm Alteogen Inc. and Chinese company Qilu Pharmaceutical Co. Ltd. to complete development of a biosimilar drug suggests the technology gap between the two countries is closing, and underlines the fact that recent political tensions between the two countries have had little impact on the biotech industry.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 17 18 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe